Farasat Bokhari is a Senior Lecturer (Associate Professor) in the School of Economics and Centre for Competition Policy at the University of East Anglia. He received his Ph.D. in Public Policy and Management from the Heinz School at Carnegie Mellon University, USA. Dr. Bokhari has taught at King’s College London (Lecturer, Department of Primary Care and Public Health Sciences), and Florida State University (Assistant Professor, Department of Economics), and was a post-doctoral fellow at the University of California, Berkeley (School of Public Health).
A health economist with a background in applied microeconomics, industrial organization, and a specialization in health policy, Dr. Bokhari’s research interests include competition, antitrust, and technologies in hospital and pharmaceutical industries. He also works in areas of outcomes research and research methods in health care. His research has looked at the evolution of industrial structures, innovation, the adoption and diffusion of health care technologies, managed care, economic and policy analysis of Attention Deficit/Hyper Activity Disorder (ADHD) and the market for psychostimulant drugs. His current work focuses on the valuation of new pharmaceutical products used in the treatment of ADHD, including generics and second generation drugs (`me-too' drugs) as well as their associated regulatory and market mechanisms (pay-to-delay, parallel trade, etc.).
As an applied economist, Dr. Bokhari has expertise working with large datasets. He has used American Hospital Association datasets to explain how the degree of competition among hospitals, relative to the degree of competition among managed care organizations in local markets, effects bargaining between these organizations, the profitability of hospitals and ultimately the adoption and diffusion of new technologies among hospitals. He has also collected, linked and maintained large datasets on the utilization of therapeutically equivalent pharmaceutical products for the treatment of ADHD, and used these to develop and estimate models of demand and substitution patterns among various choices.
His research has been published by leading academic journals including The Journal of Competition Law and Economics, The Journal of Industrial Economics, The International Journal of Industrial Organization, The Journal of Health Economics, and Health Economics.
US-backed vaccine patent waiver: pros and cons explained
May 09, 2021 08:55 am UTC| Health
The Biden administration has now agreed to back a proposal to suspend intellectual property protection for COVID vaccines. This is a break from US governments long-held position on strong intellectual property protection,...
The logic of selling cheaper 'generics' for drug companies such as Mylan
Sep 03, 2016 11:05 am UTC| Insights & Views Business
Mylan is the latest pharmaceutical company to face controversy over its drug pricing. It has come under scrutiny and strong criticism from the public and government officials for raising the price of its EpiPen allergy...
Johannesburg in a time of darkness: Ivan Vladislavić’s new memoir reminds us of the city’s fragility
Labour can afford to be far more ambitious with its economic policies – voters are on board
Sudan: civil war stretches into a second year with no end in sight